Abstract:RNA interference (RNAi) provides researchers with a versatile means to modulate target gene expression. The major forms of RNAi molecules, genome-derived microRNAs (miRNAs) and exogenous small interfering RNAs (siRNAs), converge into RNA-induced silencing complexes to achieve posttranscriptional gene regulation. RNAi has proven to be an adaptable and powerful therapeutic strategy where advancements in chemistry and pharmaceutics continue to bring RNAi-based drugs into the clinic. With four siRNA medications already approved by the US Food and Drug Administration (FDA), several RNAi-based therapeutics continue to advance to clinical trials with functions that closely resemble their endogenous counterparts. Although intended to enhance stability and improve efficacy, chemical modifications may increase risk of off-target effects by altering RNA structure, folding, and biologic activity away from their natural equivalents. Novel technologies in development today seek to use intact cells to yield true biologic RNAi agents that better represent the structures, stabilities, activities, and safety profiles of natural RNA molecules. In this review, we provide an examination of the mechanisms of action of endogenous miRNAs and exogenous siRNAs, the physiologic and pharmacokinetic barriers to therapeutic RNA delivery, and a summary of the chemical modifications and delivery platforms in use. We overview the pharmacology of the four FDA-approved siRNA medications (patisiran, givosiran, lumasiran, and inclisiran) as well as five siRNAs and several miRNA-based therapeutics currently in clinical trials. Furthermore, we discuss the direct expression and stable carrier-based, in vivo production of novel biologic RNAi agents for research and development. SIGNIFICANCE STATEMENT In our review, we summarize the major concepts of RNA interference (RNAi), molecular mechanisms, and current state and challenges of RNAi drug development. We focus our discussion on the pharmacology of US Food and Drug Administration-approved RNAi medications and those siRNAs and miRNA-based therapeutics that entered the clinical investigations. Novel approaches to producing new true biological RNAi molecules for research and development are highlighted.

Leveraging Therapeutic Potential of Multi-Targeted Sirna Inhibitors

Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application

Therapeutic siRNA: State-of-the-Art and Future Perspectives

Nanoparticle‐Mediated Sirna Delivery and Multifunctional Modification Strategies for Effective Cancer Therapy

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

RNAi-based drug design: considerations and future directions

RNA-based Therapeutics: an Overview and Prospectus

Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry

The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market

RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies

Current progress of siRNA/shRNA therapeutics in clinical trials

Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine

RNA interference in the era of nucleic acid therapeutics

In vivo self-assembled small RNAs as a new generation of RNAi therapeutics

Chemical Modification and Delivery System of Small Interfering RNA Drugs

siRNA therapeutics: a clinical reality

Synthetic SiRNA Delivery: Progress and Prospects

Clinical advances of siRNA therapeutics

Small interfering RNA for experimental cancer therapy.

Strategies, design, and chemistry in siRNA delivery systems

siRNA therapeutics: insights, challenges, remedies and future prospects